Rating- neutral; Pharma sector- Poised for strong growth in Q1FY24
时间:2024-06-26 13:22:58 阅读(143)
We anticipate a positive performance from our pharmaceutical sector coverage in Q1FY24, driven by improved sales in the US market and strong performance across most branded markets. As the cost pressures gradually ease, we expect to see a robust y-o-y Ebitda growth of 22% (excluding BIOS and Mankind). In the hospital segment, we project a relatively stable performance compared to the previous quarter, with occupancy trends gradually returning to pre-Covid levels. For diagnostic companies, we anticipate a slight increase in non-Covid realisations per patient on a quarterly basis, supported by price hikes and higher volumes of non-Covid tests. Our top picks in the pharma sector are Sun Pharma (SUNP), Mankind, and Cipla. Although recent price increases may limit short-term upside, we maintain a positive outlook on APHS, Rainbow, and KIMS in the healthcare services sector.
Pharma: Improved US, healthy branded markets, yoy margin expansion in store
Hospitals: Steady quarter in store We expect a sequentially steady performance for the India-based hospitals, with lower occupancies being offset by higher ARPOB. For hospitals, we forecast a topline growth of 15% y-o-y in Q1FY24. Overall, we expect an Ebitda growth of 20% y-o-y for our hospitals.
Diagnostics: We expect an uptick in B2C sales growth
Regarding the diagnostic firms, we anticipate a slight increase in non-Covid revenue per patient q-o-q, supported by price adjustments and higher volumes of non-Covid tests. We have factored in a y-o-y growth of 8-12% in non-Covid sales for DLPL and METROHL. We expect a decrease in Covid-related sales for both compared to the last quarter. In Q1FY24, we project a 20% q-o-q Ebitda growth rate for DLPL and a 2% q-o-q growth rate for METROHL. The lower growth rate for METROHL is due to the loss of the NACO contract, which accounted for 4-5% of sales, starting from February 2023.
下一篇:Windfall taxes on oil exports slashed- Oil stocks surge, Reliance Industries biggest beneficiary
猜你喜欢
- Share Market Highlights- Nifty settles below 19130, Sensex below 64050; Bank Nifty sheds over 310 points
- Share Market Highlights- Nifty settles above 19750, Sensex above 65,900, Realty and Media stocks shine
- Share Market Highlights- Nifty settles above 19700, Sensex over 66100; Pharma, PSU Bank, FMCG stocks shine
- Share acquisition case- Won’t force Sebi to give documents to Reliance Industries, says Supreme Court
- FII DII data- FPI sold shares worth Rs 932
- FII DII data- FPI bought shares worth Rs 1785
- The Souled Store partners with Simpl to strengthen its e-commerce platform
- Share Market Highlights- Nifty settles above 19800, Sensex over 66000; Bank Nifty sheds over 230 points
- F&O Outlook- Nifty may fall towards 16500 in near term; support in 16300-16200 range, resistance at 17000